{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:35:00Z","timestamp":1790660100967,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,1,28]],"date-time":"2009-01-28T00:00:00Z","timestamp":1233100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objective:\u2002<\/jats:bold> Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II\/III studies have shown that oral deferasirox 20\u201330\u2003mg\/kg\/d reduces iron burden, depending on transfusional iron intake.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> The prospective, open\u2010label, 1\u2010yr ESCALATOR study in the Middle East was designed to evaluate once\u2010daily deferasirox in patients \u22652\u2003yr with \u03b2\u2010thalassaemia major and iron overload who were previously chelated with deferoxamine and\/or deferiprone. Most patients began treatment with deferasirox 20\u2003mg\/kg\/d; doses were adjusted in response to markers of over\u2010 or under\u2010chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of \u22653\u2003mg Fe\/g dry weight (dw) if baseline LIC was \u226510\u2003mg Fe\/g dw, or final LIC of 1\u20137\u2003mg Fe\/g dw for patients with baseline LIC of 2 to &lt;10\u2003mg Fe\/g dw.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Overall, 233\/237 enrolled patients completed 1\u2003yr\u2019s treatment. Mean baseline LIC was 18.0\u2003\u00b1\u20039.1\u2003mg Fe\/g dw, while median serum ferritin was 3356\u2003ng\/mL. After 1\u2003yr\u2019s deferasirox treatment, the intent\u2010to\u2010treat population experienced a significant treatment success rate of 57.0% (<jats:italic>P<\/jats:italic>\u2003=\u20030.016) and a mean reduction in LIC of 3.4\u2003mg Fe\/g dw. Changes in serum ferritin appeared to parallel dose increases at around 24\u2003wk. Most patients (78.1%) underwent dose increases above 20\u2003mg\/kg\/d, primarily to 30\u2003mg\/kg\/d. Drug\u2010related adverse events were mostly mild to moderate and resolved without discontinuing treatment.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> The results of the ESCALATOR study in primarily heavily iron\u2010overloaded patients confirm previous observations in patients with \u03b2\u2010thalassaemia, highlighting the importance of timely deferasirox dose adjustments based on serum ferritin levels and transfusional iron intake to ensure patients achieve their therapeutic goal of maintenance or reduction in iron burden.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2009.01228.x","type":"journal-article","created":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T03:05:46Z","timestamp":1233198346000},"page":"458-465","source":"Crossref","is-referenced-by-count":117,"title":["Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron\u2010overloaded patients with <b>\u03b2<\/b>\u2010thalassaemia: the ESCALATOR study"],"prefix":"10.1111","volume":"82","author":[{"given":"Ali","family":"Taher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"El\u2010Beshlawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen S.","family":"Elalfy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusai","family":"Al Zir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahina","family":"Daar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Habr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Kriemler\u2010Krahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel","family":"Hmissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al Jefri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000203853"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02357-6"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.739"},{"key":"e_1_2_6_5_2","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once\u2010daily, orally\u2010administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_6_2","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once\u2010daily oral chelating agent, in paediatric patients with \u03b2\u2010thalassaemia major","volume":"91","author":"Galanello R","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430"},{"key":"e_1_2_6_8_2","article-title":"A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once\u2010daily oral iron chelator deferasirox (Exjade\u00ae, ICL670) is well tolerated and reduces iron burden","volume":"106","author":"Vichinsky E","year":"2006","journal-title":"Blood"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.3193.3193","article-title":"A phase II study with ICL670 (Exjade\u00ae), a once\u2010daily oral iron chelator, in patients with various transfusion\u2010dependent anemias and iron overload","volume":"104","author":"Porter J","year":"2004","journal-title":"Blood"},{"key":"e_1_2_6_10_2","first-page":"447","article-title":"Classification and diagnosis of iron overload","volume":"83","author":"Piperno A","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109306"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310136"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(95)80226-6"},{"key":"e_1_2_6_14_2","first-page":"1","article-title":"CDC growth charts: United States","volume":"314","author":"Kuczmarski RJ","year":"2000","journal-title":"Adv Data"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310903"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310902"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907083410207"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3167"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02760702"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004310050711"},{"key":"e_1_2_6_21_2","article-title":"Response of myocardial T2* to oral deferasirox monotherapy for 1\u2003year in 29 patients with transfusion\u2010dependent anaemias; a subgroup analysis","volume":"91","author":"Eleftheriou P","year":"2006","journal-title":"Haematologica"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2009.01228.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2009.01228.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:45:14Z","timestamp":1696967114000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2009.01228.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,21]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1600-0609.2009.01228.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01228.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,21]]}}}